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pithelial mesenchymal transformation (EMT) of the
medial edge epithelial (MEE) seam creates palatal
conﬂuence. This work aims to elucidate the molecular
mechanisms by which TGF
 
 
 
3
 
 brings about palatal seam
EMT. We collected mRNA for PCR analysis from individual
transforming MEE cells by laser microdissection techniques
 
and demonstrated that TGF
 
 
 
3
 
 stimulates lymphoid-enhancing
factor 1 (LEF1) mRNA synthesis in MEE cells. We show with
antisense 
 
 
 
-catenin oligonucleotides that up-regulated LEF1
is not activated by 
 
 
 
-catenin in palate EMT. We ruled out
E
 
other TGF
 
 
 
3
 
 targets, such as RhoA and MEK1/2 pathways,
and we present evidence using dominant-negative Smad4
and dominant-negative LEF1 showing that TGF
 
 
 
3
 
 uses
Smads both to up-regulate synthesis of LEF1 and to activate
LEF1 transcription during induction of palatal EMT. When
phospho-Smad2 and Smad4 are present in the nucleus,
LEF1 is activated without 
 
 
 
-catenin. Our paper is the ﬁrst to
show that the Smad2,4/LEF1 complex replaces 
 
 
 
-catenin/
LEF1 during activation of EMT in vivo by TGF
 
 
 
3
 
.
 
Introduction
 
During the fusion of mouse embryo palatal shelves, some of
the cells of the outer layers of the opposed medial edge
epithelia (MEE) slough off, allowing the lateral surfaces of
the underlying epithelial layers to contact each other and to
adhere to form a midline seam. This seam subsequently
transforms from epithelium completely to mesenchyme
(Fitchett and Hay, 1989; Griffith and Hay, 1992; Shuler et
al., 1992). The formation of the MEE seam activates as yet
unknown signals that endow component epithelial cells with
a competence to respond to TGF
 
 
 
3
 
 to create confluence of
the palatial shelves by epithelial mesenchymal transformation
(EMT). One cause of the birth defect, cleft palate, is failure
in the EMT step of palate development, although failure
of the other steps in palatogenesis, such as palatal growth,
elevation, and adherence between paired shelves can also
cause clefts. TGF
 
 
 
3
 
 signaling has been known for sometime
to be essential for palatogenesis (Kaartinen et al., 1995; Proetzel
et al., 1995), as it activates EMT in the MEE seam (Sun
et al., 1998; Cui and Shuler, 2000). However, TGF
 
 
 
3 
 
is
not essential for adherence of the MEE seam (Sun et al.,
1998), which is brought about by E-cadherin–dependent
desmosomes.
The evidence for EMT of the MEE seam consists of cyto-
logical descriptions and cell-tracing experiments showing
that the adherent seam breaks up into islands that become
mesenchyme (Fitchett and Hay, 1989; Griffith and Hay,
1992; Shuler et al., 1992; Sun et al., 1998, 2000). The
source of the mesenchymal cells could be identified with
transmission electron microscopy (TEM) by the remnants of
epithelium carried on their surfaces as they detached, e.g.,
desmosomes (Fitchett and Hay, 1989). The transforming
epithelial cells send out filopodia that disrupt the basement
membrane. The cells become elongated in cell shape and
migrate into preexisting connective tissue, acquiring all the
cytological features of mesenchymal cells (Fitchett and Hay,
1989). Griffith and Hay (1992) used carboxyfluorescein
(CCFSE) for TEM, which is taken up by epithelia and pack-
aged into insoluble isolation bodies. The latter allow labeled
cells transforming from the MEE seam to be identified as
epithelial in origin by TEM (Griffith and Hay, 1992). The
advantage of CCFSE is that it is never transferred from cell
to cell (Sun et al., 2000). Thus, elongated cells with mesen-
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chymal morphology derived from MEE are easily identified
by TEM some distance from the midline in confluent pal-
ates (Griffith and Hay, 1992). Shuler et al. (1992) used 
 
DiI
 
to document this transformation by light microscopy.
Thus far, the only major signaling pathway that has been
consistently been shown to be directly involved in transfor-
mation of epithelium to mesenchyme is 
 
 
 
-catenin/lym-
phoid-enhancing factor 1 (LEF1; Hay, 2003; Kim et al.,
2002), but whether or not 
 
 
 
-catenin will activate LEF1 de-
pends on specific isoforms of LEF/TCF transcription factor
that contain an alternative COOH-terminal “E” tail (Atcha
et al., 2003). This restriction raises the possibility of LEF1
activation by other non-
 
 
 
-catenin mechanisms. Recent pa-
pers by Labbe et al. (2000) and Nishita et al. (2000) have
shown that LEF1 can also be activated by other factors, such
as Smads. Another transcription factor that has been impli-
cated is Snail by repressing E-cadherin (Cano et al., 2000).
Previous works showed that activation of 
 
 
 
-catenin/LEF1 is
associated with c-Fos–induced EMT in mammary cells
(Eger et al., 2000; El-Tanani et al., 2001) and with ILK-
mediated EMT (Novak et al., 1998), as well as with me-
tastasis in carcinomas (Morin et al., 1997; El-Tanani et al.,
2001). Kim et al. (2002) demonstrated that LEF1 adminis-
tered in an adenovirus directly induces EMT in colon carci-
nomas, and we show here that LEF1 is present in the epithe-
lium of maxillary processes preparing to undergo EMT.
LEF
 
 
 
/
 
 
 
 mice have severe craniofacial deformities (Duan et
al., 1999), suggesting that the LEF1 gene plays an important
role in cranial embryogenesis.
TGF
 
 
 
 is a secreted cytokine that has a diversity of biolog-
ical effects including pivotal roles during embryonic devel-
opment (Nakajima et al., 1994; Boyer et al., 1999). Induc-
tion of EMT by TGF
 
 
 
 has been studied in vitro in many
different epithelial cells types, including mouse mammary
cell lines (Miettinen et al., 1994; Piek et al., 1999) and hu-
man keratinocytes (Zavadil et al., 2001). In vivo, TGF
 
 
 
plays a role in cardiac valve induction and correlates with
EMT (Runyan et al., 1992). The TGF
 
 
 
 homodimer signals
through the Smad pathway using transmembrane serine/
threonine kinase receptors designated as TGF
 
 
 
 type I
(T
 
 
 
RI) and type II (T
 
 
 
RII) receptors (Lin et al., 1992;
Wrana et al., 1992; Lutz and Knaus, 2002). Phospho-
Smad3 is not present in the MEE (Cui et al., 2003), but
phospho-Smad2 and 4 are well represented. Under ideal
conditions, Smad2 phosphorylation and transport into the
nucleus by Smad4 (Abdollah et al., 1997) is promoted by
TGF
 
 
 
 receptors (Itoh et al., 2003), early endosomes (Pan-
opoulou et al., 2002), and Smad anchor for receptor activa-
tion (SARA) (Tsukazaki et al., 1998; Itoh et al., 2002). PI3
kinase, which can modulate SARA via FYVE, has also been
shown to be involved in palatal EMT (Kang and Svoboda,
2002). In the nucleus, Smads bind to a specific DNA site
(GTCTAGAC) and cooperate with various transcription
factors in regulating target gene expression (Ten Dijke et al.,
2002). The induced Smad2/Smad4 heteromeric complexes
in polyamine-deficient cells are able to bind to this specific
DNA site, suggesting that Smads mediate transcriptional ac-
tivation (Liu et al., 2003).
Non-Smad pathways have also been implicated in TGF
 
 
 
signaling (Bhowmick et al., 2001; Roberts, 2002). There is
evidence in vitro that TGF
 
 
 
 induces mesenchyme-like cells
containing actin stress fibers independently of Smads, using
the Ras-Raf-MEK-ERK (Mulder, 2000) and RhoA-Rac-
MAPK-JNK-Jun pathways (Bhowmick et al., 2001; Roberts,
2002). However, production of stress fibers does not define
EMT (Hay, 1995). Yu et al. (2002) demonstrated that TGF
 
 
 
signaling through MAPK/MEK does not initiate EMT.
Kaartinen et al. (2002) reported that activation of the RhoA
kinase pathway is not sufficient for palatal EMT. TGF
 
 
 
-
induced EMT was found to require T
 
 
 
R, and thus to use
Smad (Itoh et al., 2003). By inhibiting RhoA and MEK path-
ways, we show that they are not involved in palatal EMT.
Our major objective is to elucidate the roles of TGF
 
 
 
3
 
and LEF1 during palatal EMT. We show that TGF
 
 
 
3
 
 acts
via LEF1 to induce mouse palatal EMT not only by up-reg-
ulating LEF1 mRNA, but also by transcriptional activity of
LEF1. Without Smads, palatal EMT cannot be achieved by
LEF1. There is little or no involvement of 
 
 
 
-catenin in the
activation of palatal EMT by LEF1. This paper provides the
first evidence of a Smad-activated LEF1 mechanism driv-
ing EMT in development. It is tempting to hypothesize
that TGF
 
 
 
3
 
-initiated Smad-dependent LEF1 pathways will
prove to be the major regulators of embryonic EMT.
 
Results
 
First, we established that normal mouse (CF1) palates are
completely confluent at 60 h (Fig. 1, A–D). Other mouse
strains, such as Swiss Webster, usually take 72 h for com-
plete transformation (Cui and Shuler, 2000). During nor-
mal palate development in vitro or in vivo in the CFW1
mouse, opposed palatal shelves adhere by 12 h after contact
to form the 2–3-cell-wide MEE seam (Fig. 1 A, arrow) that
breaks up into islands (Fig. 1 B) during transformation into
mesenchyme. The transformation is well underway by 48 h
(Fig. 1 C) and is complete by 60 h, when all cells in the
MEE have achieved typical mesenchymal characteristics
(Fig. 1 D).
 
The role of TGF
 
 
 
3
 
 in palatal EMT does not involve its 
non-Smad pathways
 
It has been proved experimentally that it is the EMT step of
avian palatogenesis that requires TGF
 
 
 
3
 
 (Sun et al., 1998).
As expected, treatment of mouse palates with blocking
TGF
 
 
 
3
 
 antibody does not affect the cadherin-dependent ad-
herence of the MEE seam, but does prevent its transforma-
tion to mesenchyme (Fig. 1, E and F; arrows). TGF
 
 
 
3
 
-
blocking antibody inhibits epithelial cell transformation to
mesenchyme by preventing binding of endogenous TGF
 
 
 
3
 
to the receptors that initiate EMT signals. The result is that
the MEE fails to transform.
In addition to Smad pathways, TGF
 
 
 
 has recently been
shown to induce EMT in vitro by two non-Smad path-
ways, RhoGTPase-Rac-MEK-JNK (Bhowmick et al., 2001)
and Ras-Raf-MEK1/2-ERK (Janda et al., 2002). We used
 
Clostridium botulinum
 
 C3 (hereafter referred to as C3) to dis-
rupt RhoA by inducing ADP ribosylation of RhoA protein at
Asn41, which inactivates downstream signaling of Rho GTP-
ases (Zubiaur et al., 1995). We used MEK1/2 inhibitor
U0126 (Favata et al., 1998) to explore a possible role of this 
Smads activate the LEF1 gene in palatial EMT |
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pathway. With C3 or U0126, palatal shelves form MEE by
12 h (Fig. 1, G and J) and proceed (Fig. 1, H, I, and K) to
complete the EMT by 60 h (Fig. 1 L), the same as normal
palates (Fig. 1, A–D). Thus, MEK1/2 and RhoA have no de-
tectable effects on TGF
 
 
 
3
 
-mediated palatogenesis.
We evaluated the effects of these inhibitors by quantitat-
ing morphological data (Fig. 2). Fig. 2 shows the number of
cells in the MEE seam at different times (12–60 h) of palate
development. They were counted in cross sections of frozen
palates using Leica software for laser capture microdissection
Figure 1. Effect of inhibitors of TGF 3, RhoA, and MEK pathways on palatal EMT. Hematoxylin and eosin-stained sections of palates fixed 
at different stages of palatogenesis (A–D) and after treatment with TGF 3-blocking antibody (E and F), C3 (G–I) and U0126 (J–L). (A–D) Normal 
palatal shelves adhere to form the MEE seam by 12 h (A, arrow) Then, at 24 h the seam starts to break into small islands of epithelial cells (B). 
By 48 h, a few remnants of MEE are left (C). EMT is complete by 60 h (D, arrow). (E and F) Palates treated with anti-TGF 3 antibody (2 ng/ L) 
form a seam (E, arrow) by 12 h, but do not transform the MEE by 60 h (F, arrow). (G–I) Palates treated with C3, a RhoA inhibitor, form an MEE 
by 12 h (G, arrow) that transforms into mesenchyme by 24–48 h (H and I). The palates reach complete confluence by 60 h (not depicted). 
(J–L) Palates treated with U0126, a MEK1/2 inhibitor, form MEE seams that also undergo transformation (J, 24 h; K, 36 h) to complete EMT at 
60 h (L, arrow). There were no effects of RhoA inhibitor (C3) or MEK inhibitor (U0126) on normal palatogenesis. 
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(LCM; see Materials and methods). A section of untrans-
formed seam contains 62–96 epithelial cells with an average
of 76. We staged palatogenesis according to the number of
epithelial cells left in sections of the seam (see legend for Fig.
2). The untreated control is shown in Fig. 2 A (a). The intact
seam is stage 6 at 12 h; 60–76 cells remain in the seam at 18 h,
stage 5; 40–59 cells at 24 h, stage 4; 20–39 cells at 36 h,
stage 3; 1–19 cells at 48 h, stage 2; and no cells, representing
complete transformation (confluence), at 60 h, stage 1.
C3 (Fig. 2 A, c) and U0126 (Fig. 2 A, d) are seen in this
graph to have no effect on palatal EMT. The timing of
stages 1–6 is exactly the same as the control (Fig. 2 A, a).
The data shown here also confirm the role of TGF
 
 
 
3
 
 in pal-
atal EMT. Treatment with TGF
 
 
 
3
 
 antibody arrests the
MEE seam at stage 6 (Fig. 2 A, b). These data strongly sup-
port the idea that endogenous TGF
 
 
 
3
 
 does not cause EMT
in this system by non-Smad pathways.
 
 
 
-Catenin remains in the cytoplasm during palatal EMT
 
Next, we tested the hypothesis that TGF
 
 
 
3
 
 induces palatal
EMT via the 
 
 
 
-catenin/LEF1 or Wnt pathway, because it
has recently been shown to directly mediate a number of
EMTs (Kim et al., 2002). We found that the MEE does not
transform at all in presence of dominant-negative (DN)
LEF1 (Fig. 2 B, b; remain at stage 6), indicating that the
 
 
 
-catenin/LEF1 pathway is needed for palatal EMT.
To examine these interrelations, we analyzed the effects of
TGF
 
 
 
3
 
 on LEF1 mRNA synthesis and subsequent transport
of 
 
 
 
-catenin/LEF1 to the nucleus. To our surprise, we de-
tected no 
 
 
 
-catenin in the palatal nuclei before, during, or
after EMT in untreated palates (Fig. 3, A and B), nor in pal-
ates treated with either LEF1 (Fig. 3, C–F) or DN Smad4
(Fig. 3 G), indicating 
 
 
 
-catenin paucity characterizes nor-
mal palates. Because immunofluorescence is not a quantita-
tive method, we cannot rule out the presence of very small
amounts of 
 
 
 
-catenin in these nuclei. However, the data are
clear cut enough to support the hypothesis that palatal LEF1
transcriptional activity depends on Smads, not 
 
 
 
-catenin
(Labbe et al., 2000).
To explore the possible role of 
 
 
 
-catenin, which normally
is responsible for activation of LEF1 transcription, in palato-
genesis, we treated normal palates undergoing EMT with
sense and antisense (AS) 
 
 
 
-catenin oligonucleotide and
found that AS 
 
 
 
-catenin significantly reduces 
 
 
 
-catenin pro-
tein levels compared with sense (Fig. 3, H and I). However,
AS 
 
 
 
-catenin has no inhibitory effects on EMT at all (Fig. 2
B, d). Thus, normal palate does not use 
 
 
 
-catenin for EMT.
 
LCM and quantification of LEF1 mRNA during 
palatal EMT
 
To study the process further by which TGF
 
 
 
3
 
 up-regulates
LEF1 during palatal EMT, we used a new technique, LCM,
to obtain cells from the MEE seams to measure their metab-
olism by highly sensitive real-time PCR. We demonstrated
that LEF1 gene expression reaches a peak in MEE cells at
the onset of EMT during palate development. Endogenous
LEF1 mRNA is expressed at 12 h (Fig. 4 A, a) and gradually
increases to a peak by 36 h of incubation, dropping at 48 h
before complete confluence at 60 h, when no MEE epithe-
lial cells remain. The high level of LEF1 mRNA expression
at 36 h is at the high point of transformation by the normal
epithelial seam. Even though LEF1 levels fall after 36 h,
enough is present for cells to complete transformation.
When normal palates were treated with exogenous LEF1 vi-
rus, the expression of LEF1 mRNA by MEE cells increased
over the control to reach peak by 24 h instead of 36 h, and
decreased by 48 h (Fig. 4 A, b).
By quantitative PCR, we also show that palates treated
with blocking antibodies to TGF
 
 
 
3
 
, DNLEF1, and DN
Smad4 do not express LEF1 mRNA (Fig. 4 A, c and d; Fig.
4 B, c). MEE seams treated with TGF
 
 
 
3
 
-blocking antibody
(Fig. 1, E and F; Fig. 2 A, b), DN LEF1 (Fig. 2 B, b), or DN
Smad4 (Fig. 2 B, c) remain in stage 6, i.e., they do not trans-
form. Inhibition of the endogenous expression of LEF1
mRNA (Fig. 4 A, c and d; Fig. 4 B, c) results in no transfor-
mation of MEE seam.
As LEF1 mRNA synthesis and seam EMT are inhibited
by TGF
 
 
 
3
 
-blocking antibody, DN LEF1, or DN Smad4,
we expected that exogenous LEF1 would rescue inhibition
of palatal EMT by TGF
 
 
 
3
 
-blocking antibody (Fig. 2 B, a),
but it did not. This was a surprise because the DN LEF1 re-
sults (Fig. 2 B, b; Fig. 5 E) indicate that LEF1 is required for
EMT. Correlations indicate that LEF1 mRNA peaks at 36 h
Figure 2. Quantification of disappearance of cells from epithelial 
seam during EMT. Using LCM on 8- m-thick frozen sections from 
the middle one third of the palate, we estimated cell numbers in 
each section of the MEE seam from 12 to 60 h after the beginning 
of the culture. On the ordinate, we estimated seam transformation 
by the number of cells remaining in it. Stage 1, 0 cells (confluence); 
stage 2, 1–19 cells; stage 3, 20–39 cells; stage 4, 40–59 cells; stage 
5, 60–76 cells; stage 6, untransformed seam (75 cells). Palates were 
treated from the beginning of culture with the following reagents: 
TGF 3-blocking antibody, TGF 3-blocking antibody plus LEF1, 
RhoA inhibitor C3, MEK1/2 inhibitor U0126, DN LEF1 virus, DN 
Smad4 adenovirus, and AS  -catenin. A (a) is the untreated control. 
Length of time is indicated by the decoration inside the graph bars. 
Untreated/control palates are confluent by 60 h (A, a), and palates 
treated with anti-TGF 3 antibody do not transform (A, b). Treatment 
with C3 (A, c), U0126 (A, d), and AS  -catenin (B, d) have no effect 
on MEE seam transformation. LEF1 does not rescue blockage by 
anti-TGF 3 antibody (B, a). Treatment with DN LEF1 (B, b) or DN 
SMAD4 (B, c) inhibits transformation. 
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and remains significantly up-regulated until EMT is com-
pleted at 60 h (Fig. 4 A, a). The amount of LEF1 mRNA is
substantial (Fig. 4 B, a). This result can be explained by a
need for a constant source of phospho-Smad2 not only to
up-regulate levels of LEF1, but also to activate LEF1 tran-
scription (Attisano and Tuen Lee-Hoeflich, 2001) in order
to bring about EMT during palatogenesis.
We also used real-time quantitative PCR techniques to
compare the effects of Smad-independent signaling on
LEF1 mRNA levels during the EMT phase of palatogene-
sis when non-Smad pathways are inhibited. Inhibition of
RhoA with C3 (Fig. 4 B, d) and MEK1/2 with U0126
(Fig. 4 B, e) did not alter normal LEF1 mRNA levels or
affect palatal EMT. AS 
 
 
 
-catenin also has no effect on
LEF1 mRNA (Fig. 4 B, b), confirming that it is not in-
volved in normal palatal EMT.
 
LEF1 and Smads interact to mediate the effects 
of TGF
 
 
 
3
 
 on palatal EMT
 
It is well within the realm of possibility that many natural
EMTs, regulated by TGF 3, use Smad/LEF1 instead of
 -catenin complexes to activate LEF1. That this is so for
the palate is shown by the following data. We showed that
AS  -catenin does not inhibit normal MEE transformation
(Fig. 2 B, d; Fig. 5, A–D). Thus,  -catenin is not normally
used in palatal EMT. We confirmed that morphology of
the AS  -catenin–treated palates is the same as normal pal-
ates (Fig. 5, A–D). They reach confluence by EMT at ex-
actly the same time as normal palates (Fig. 1, A–D; Fig. 2
A, c and d). Because  -catenin has no role in palatal EMT,
it is not a reasonable candidate for the necessary interac-
tions with LEF1 during activation of LEF1 transcription.
Palate EMT must be using Smad/LEF1, which already has
Figure 3. Expression of  -catenin in treated and/or untreated palates during different stages of palatogenesis. A and B are stained with a 
fluorescein antibody (green) that recognizes  -catenin. C–I are stained with a rhodamine antibody (red) that recognizes  -catenin because 
some of the probes used there (e.g., LEF1) contained GFP. (A and B)  -Catenin expression can be detected by immunofluorescence in untreated 
paired palates.  -Catenin is located on the cell surface and/or cytoplasm of the MEE and transforming epithelial cells (A, 24 h; B, 48 h), but 
not in nuclei (arrows). (C–F) Administration of the LEF1 adenovirus fails to up-regulate  -catenin in the nuclei (arrows) of the transforming 
seams (C, 12 h; D, 24 h; E, 36 h; F, 48 h). (G) Administration of DN Smad4 adenovirus also does not affect pattern of  -catenin expression as 
compared with normal palatal MEE (E). Rhodamine-conjugated  -catenin antibody staining reveals expression of  -catenin only within the 
cytoplasm. (H and I) AS  -catenin oligonucleotide (I) significantly inhibits  -catenin expression, but sense treatment does not (H). There is no 
inhibitory effect of these oligodeoxynucleotides on EMT, because palatal EMT is not dependent on  -catenin (see text).1296 The Journal of Cell Biology | Volume 163, Number 6, 2003
been shown by others to activate LEF1 transcription (Labbe
et al., 2000).
To restore EMT in TGF 3-blocked palates treated with
LEF1 (Fig. 2 B, a), active TGF 3 and LEF1 are required.
We showed here that TGF 3 only promotes palatal EMT
through Smads and LEF1-dependent pathways. Thus, the
addition of TGF 3 undoubtedly adds the Smads that are
needed to activate LEF1. We showed that palates treated
with either DN LEF1 or DN Smad4 adenovirus do not un-
dergo EMT (Fig. 2 B, b and c), and LEF1 mRNA expres-
sion is significantly reduced (Fig. 4 A, d; Fig. 4 B, c). The
palatal shelves adhere to form normal MEE, but the EMT
process is completely abolished by DN Smad4, and MEE re-
main untransformed (Fig. 5 F). These palates recover com-
pletely when phospho-Smads are available to interact with
LEF1. This interaction has been documented and analyzed
(Labbe et al., 2000), and is the only known way that LEF1
transcription can be activated in the absence of  -catenin.
Moreover, we show below that phospho-Smad2 must be in
the nucleus (Fig. 6) to activate LEF1 transcription, where it
interacts with LEF1.
Smad2 is activated and present in the nucleus during 
palatal EMT
Phospho-Smad2, an important signaling molecule of the
TGF 3 pathway, can easily be detected in the nucleus of
normal MEE seam cells by antibodies to phospho-Smad2
protein (Fig. 6 A, arrow), but phospho-Smad3 is not
present (Cui et al., 2003). Phospho-Smad2 remains in the
MEE cytoplasm when palates are treated with DN Smad4
(Fig. 6 B, arrow), because active Smad4 is not available to
Figure 4. LEF1 gene expression (real-time quantitative PCR). 
LEF1 mRNA expression was measured by highly sensitive real-time 
PCR in LCM-dissected MEE cells from frozen sections. (A) Palates 
were treated with exogenous LEF1 virus, anti-TGF 3 antibody, DN 
LEF1 virus, and exogenous recombinant TGF 3. (B) Palates were 
treated with exogenous LEF1 virus plus anti-TGF 3-blocking anti-
body, AS  -catenin oligodeoxynucleotide, DN Smad4 adenovirus, 
C3, a Rho inhibitor, and U0126, a MEK1/2 inhibitor. Length of time 
is indicated within each graph bar, as in Fig. 2. (A, a) In the un-
treated palates (Untr/Cntrl), LEF1 expression peaks at 36 h, at which 
time EMT also peaks. (A, b) In presence of exogenous LEF1, there is 
a large increase in LEF1 mRNA expression that peaks at 24 h instead 
of 36 h. (A, c) TGF 3 inhibition by blocking antibody causes complete 
inhibition of LEF1 mRNA expression and EMT (A, d) DN LEF1 causes 
palates to cease endogenous LEF1 mRNA expression and remain 
untransformed. (A, e) Exogenous TGF 3 causes LEF1 mRNA and 
protein to up-regulate and reach a peak at 24 h without significantly 
hastening the EMT process. (B, a) Exogenous LEF1 DNA increases 
LEF1 mRNA, but the seam remains untransformed if palates are 
treated with TGF 3-blocking antibody. (B, b) AS  -catenin did not 
affect LEF1 mRNA expression as compared with the control (A, a). 
(B, c) DN Smad4 inhibits LEF1 mRNA expression and MEE remains 
untransformed. (B, d) RhoA inhibitor C3 had no effect on normal 
LEF1 mRNA expression or EMT, (B, c) and neither did MEK1/2 
inhibitor U0126 (B, e).
Figure 5. Palates treated with DN LEF1 and DN Smad4 do not 
undergo EMT, but normal EMT follows treatment with AS  -catenin 
oligodeoxynucleotide. Hematoxylin and eosin staining of palate 
sections 12–60 h after treatment DN LEF1 and DN Smad4 adeno-
viruses or 60 h with AS  -catenin from the beginning of culture. 
(A–D) Developing palates 12 h after treatment with AS  -catenin 
have formed an MEE seam (A, black arrow), and EMT is underway 
by 24 h (B) and 48 h (C) after treatment. Confluence is reached by 
60 h (D, white arrow) without  -catenin. Thus, palatal EMT does 
not normally use  -catenin/LEF1, and in some other way activates 
LEF1 transcription. (E and F) DN LEF1 (E) and DN Smad4 (F) treated 
palates fail to transform the MEE to mesenchyme by 60 h (black 
arrows). Thus, palatal EMT requires active LEF1 and active Smads.Smads activate the LEF1 gene in palatial EMT | Nawshad and Hay 1297
transport it to the nucleus (Fig. 6 C, arrow). As expected,
when treated with blocking TGF 3 antibody, palates do
not express phospho-Smad2 nuclear proteins (unpublished
data), and only cytoplasmic Smad2 protein is present in
the MEE cells (Fig. 6 D). A similar pattern (absence from
the nucleus) was always observed in DN Smad4-treated
palates (Fig. 6 E). Smad4 is also in the cytoplasm (Fig. 6 F)
when palatal shelves are treated with DN Smad4, effec-
tively inhibiting Smad4 nuclear translocation and EMT,
confirming that the Smad2–Smad4 complex is responsible
for TGF 3-mediated LEF1 mRNA synthesis and activa-
tion during palatal EMT.
Discussion
In this work, we investigate the nature of the TGF 3-initi-
ated signaling pathways that bring about EMT of the palatal
MEE. By PCR, we found that TGF 3 up-regulates LEF1
mRNA, and by administering DN LEF1, that LEF1 is re-
quired for TGF 3 to induce palatal EMT. However, infec-
tion with an adenovirus expressing LEF1 that induces EMT
in  -catenin–rich DLD1 cells (Kim et al., 2002) does not
rescue MEE EMT in palates blocked with anti-TGF 3.
Thus, we found that TGF 3 needs to be present in addition
to LEF1 to bring about EMT in these palates.
The discussion will focus on proposed mechanisms for
this newly described phenomenon (Labbe et al., 2000),
whereby the TGF 3 ligand turns on a series of events acti-
vating T Rs and Smads, to up-regulate LEF1 synthesis and
transcription, thereby causing palatal epithelial cells to trans-
form into mesenchymal cells. Thus, confluence by EMT of
a fusing embryonic organ in situ can be achieved in a highly
sophisticated manner.
LEF1 promotion of palatal EMT and LEF1 mRNA 
is dependent on TGF 3 signaling
This is the first paper reporting that LEF1 mRNA is up-reg-
ulated in the MEE during palatal EMT. Expression of the
LEF1 transcription factor is increased as EMT proceeds and
reaches a peak between 24 and 36 h. The mRNA level then
gradually falls, and the transformation is complete by 60 h.
We used LCM on an embryonic organ (palate) to dissect in-
dividual MEE cells for analysis of LEF1 gene expression and
quantification with real-time PCR. This is an important
new technology that permits single cells to be microdissected
as a pure population for chemical analysis from frozen sec-
tions of embryonic anlage.
To understand the unexpected enigma mentioned above
that inhibition of palatal EMT by adding TGF 3-blocking
antibody is not rescued by addition of pure LEF1, it is nec-
essary to consider the mechanisms cells use to activate LEF1
transcription that might be in use by the palate MEE. In tu-
mors and cell lines, it is common for  -catenin to activate
LEF1/TCF transcription (Morin et al., 1997; Eger et al.,
2000; Kim et al., 2002), but an astonishing variant of this
mechanism has recently been reported by Labbe et al.
(2000) and Nishita et al. (2000). Smads, which can only be
activated by TGF , have been shown to activate LEF1 tran-
scription. Thus, MEE disappearance by EMT could be
dependent on both TGF 3 and LEF1 expression. Once
TGF 3 ligands are bound to an appropriate receptor regime,
the MEE seam is the target for TGF 3 signaling involving
Smads2/4 and LEF1. Here, we show that both synthesis and
transcription of LEF1 are activated by Smads as predicted by
Labbe et al. (2000) and Nishita et al. (2000)
Smads, not  -catenin, activate LEF1 mRNA synthesis 
and transcription during palatal EMT
 -Catenin is an important partner in LEF1 transcriptional
factor activity, and when LEF1 is bound to  -catenin, LEF1
Figure 6. Immunolocalization of Smad2, phospho-Smad2, and 
Smad4 in untreated and treated (TGF 3-blocking antibody and DN 
Smad4) palates. (A) Phospho-Smad2 is intensely present in the 
nuclei of normal palatal MEE (12 h), indicating it is translocated 
by Smad4 into the nucleus (arrow) during normal palatogenesis. 
(B) Phospho-Smad2 in MEE of palates treated (36 h) with DN Smad4 
is located in the cytoplasm and no nuclear localization occurs 
(arrow), confirming that Smad4 is required for nuclear translocation 
of phospho-Smad2. (C) Unphosphorylated Smad2 is located in the 
cytoplasm of MEE cells not in the nucleus (arrow) of palates lacking 
Smad4 after 12 h of culture. (D) Smad2 is also located in cytoplasm 
of the MEE cells (36 h), but not in the nucleus (arrow) in the presence 
of blocking TGF 3, confirming that TGF 3 is required for the phos-
phorylation of Smad2. (E) Smad2 in MEE of palates (36 h) treated 
with DN Smad4 is located in the cytoplasm of the cell, but not in 
the nucleus (arrow). At this late phase, the MEE is still untransformed. 
(F) DN Smad4 inhibits the transport of Smad4 itself to the nucleus. 
Thus, nuclear Smad2/4 is not available to activate LEF1, and these 
palates do not transform.1298 The Journal of Cell Biology | Volume 163, Number 6, 2003
transports it to the nucleus (Behrens et al., 1996; Kim and
Hay, 2001). Interaction of LEF1 with nuclear  -catenin is
known to effect Wnt signaling by stimulating the activity of
LEF1/TCF transcription factors (Eastman and Grosschedl,
1999).  -Catenin is such an important component of LEF1
transcriptional activity in a variety of EMTs in vitro and in
vivo (Novak et al., 1998; Eger et al., 2000; El-Tanani et al.,
2001) that we expected to find it well represented in the nu-
clei of palate cells using LEF1 for EMT.
It came as surprise, then, to find no detectable  -catenin
in the nuclei of transforming MEE cells. Abundant  -cate-
nin is localized in the cytoplasm and cell surface during all
stages of normal palate development, but treatment with ex-
ogenous LEF1 did not move it to the nucleus. Even if a
minute amount of  -catenin is present in MEE nuclei that is
not detectable by immunofluorescence, it is unlikely that sig-
nificant  -catenin signaling through LEF1 could transform
in the MEE cells. Next, we looked at the possibility that nor-
mal palates are not using  -catenin–activated LEF1 to trans-
form the MEE to mesenchyme. We treated palates with AS
 -catenin and found it did not inhibit palatal EMT. Thus,
palates must be using some other activator for LEF1
Smads are the obvious candidates to interact with LEF1 to
activate its transcription (Labbe et al., 2000). We used DN
Smad4 to show that Smads are indeed essential for activa-
tion of LEF1 leading to palatal EMT. Moreover, we showed
by immunohistochemistry that phospho-Smad2 is present
in nuclei of the normal MEE cells during EMT at the time
that LEF1 is up-regulated by TGF 3. DN Smad4 abolishes
all nuclear Smads. We conclude that TGF 3-mediated cell
signaling during palatogenesis is not  -catenin dependent,
and that LEF1 transcriptional activity is solely Smad depen-
dent during palatal EMT.
Considering the wide-spread and successful use of  -cate-
nin to activate the LEF1 transcription factor, one might ask
why use Smads instead? There may be disadvantages in us-
ing  -catenin to activate LEF1 in some systems (Ishitani et
al., 2003). If  -catenin is bound with LEF1, TGF  may not
be able to dissociate the complex (Sasaki et al., 2003). It may
be that in vivo, it is easier to control LEF1 with Smads dur-
ing TGF 3 signaling in embryos, leaving  -catenin under
separate control in Wnt pathways. In the adult, while TGF 
signaling can be involved in carcinogenesis (Oft et al., 1998;
Cohen, 2003), the  -catenin pathway is plagued by malig-
nant mutations.
TGF 3 promotes Smad pathway, not Smad-independent 
pathways, in the MEE seam
Smads can only be activated by members of the TGF  su-
perfamily using specific receptors (Piek et al., 1999; Dennler
et al., 2002). TGF  induces phosphorylation of Smad2,
which is known to activate the LEF1 transcription factor
(Labbe et al., 2000; Nishita et al., 2000). Itoh et al. (2003)
have demonstrated that TGF -induced EMT requires intact
T RI, and thus is dependent on Smad pathway. Our data
indicate that only Smad-dependent pathways regulate palatal
EMT. Phospho-Smad2 is strongly expressed in the nuclei of
the transforming MEE. When palates are treated with DN
Smad4, Smad2 remains inactive in the cytoplasm because its
nuclear translocation depends on shuttle by Smad4. With
TGF 3-blocking antibody or DN Smad4, there is no expres-
sion of phospho-Smad2/4 in the MEE nuclei, raising the
possibility that LEF1 mRNA up-regulation depends on both
phospho-Smad2 and phospho-Smad4. Nishita et al. (2000)
found that both Smad3 and Smad4 activated LEF1 tran-
scriptional activity in the systems they analyzed. In the pal-
ate, Smad2 substitutes for Smad3 (Cui et al., 2003).
Although the Smad2/4 pathway is the only one likely to
be involved in palatal EMT, several investigators recently
have proposed TGF 3 signals EMT by Smad-independent
signaling. These pathways are RhoA-Rac-MEK-JNK (Yu et
al., 2002) and/or Ras-Raf-MEK-ERK (Mulder, 2000). C3, a
specific inhibitor of RhoA kinase, blocks RhoA-Rac pathway
(Kaartinen et al., 2002; Smith et al., 2003). U0126 com-
pletely inhibits MEK1/2, which takes place further down-
stream (Kretzschmar et al., 1999), and abolishes the path-
way involving Ras-Raf-MEK (Adnane et al., 2002). The
RhoA pathway of TGF  has been shown to activate in pal-
ates, but not to induce significant EMT (Bhowmick et al.,
2001; Kaartinen et al., 2002). Another paper concluded that
TGF 1 only induces EMT through the RhoA pathway
(Bhowmick et al., 2001). We found that treatment of pal-
ates with inhibitors of RhoA (C3) and MEK1/2 (U0126)
does not affect LEF1 mRNA expression or the palate EMT.
The fact that DN Smad4 inhibits palatal EMT also indicates
that the Smad-dependent TGF 3 signaling is required for
activation of palatal EMT.
In summary, this work has investigated the remarkable co-
operative roles of TGF 3 and LEF1 in bringing about EMT
in palatogenesis. The discovery that LEF1 is required for
palatal EMT is completely new. Also, for the first time we
present evidence that TGF 3 up-regulates LEF1 mRNA and
that Smads, not  -catenin, activate LEF1 in this embryonic
EMT. Our analysis of the palate extends the results of Labbe
et al. (2000) and Nishita et al. (2000), and makes it tempt-
ing to speculate that embryos in general might use the
TGF  pathway to turn on EMT via LEF1. This finely
tuned pathway may not be subject to the extensive muta-
tions that frequently occur in  -catenin/LEF1 pathways.
Materials and methods
40 timed pregnant CF1 mice (Charles River Laboratories) were anesthe-
tized with peritoneal Avertin (2,2,2-tribromoethanol with Tert-amyl alco-
hol; Sigma-Aldrich). Palatal shelves from 300 mouse embryos at a stage
(E14) of palate development before fusion of the shelves were dissected
under sterile conditions and placed in pairs on TSO-Agarose in organ cul-
ture dishes. Tissues were incubated at 37 C in a humidified gas mixture
(5% CO2 and 95% air), and the TSO medium was changed every 24 h.
Before and after placing palatal shelves together in pairs, they were
treated with the following molecules alone or in combination: (1) GFP full-
length LEF1 adenovirus. Full-length LEF1 with GFP was subcloned into
pAdEasy™ EGFP plasmid expressing full-length active LEF1 and GFP un-
der different CMV promoters using the adenovirus construction kit sup-
plied by Dr. B. Vogelstein (The Johns Hopkins School of Medicine, Balti-
more, MD). Generation of active LEF1 virus and DN LEF1 virus was as
described previously (He et al., 1998), and all virus probes were carefully
tested for activity (Kim et al., 2002). Palates transfected with 200  l of 1.0
 g/ml LEF1 adenovirus in TSO buffer express LEF1 and undergo EMT. (2)
GFP DN LEF1 adenovirus. A LEF1 construct coding aa 1–373 in the EVR-
FL9b plasmid was the gift of Dr. Marian Waterman (University of Califor-
nia, Irvine, Irvine, CA). A Kozak sequence, KPN1 restriction site, and start
site were inserted upstream of the LEF1 s amino acid, and a stop codon
and Xba restriction site were added downstream of aa 313 (bp 939) to de-
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PCR fragment was inserted into pAdEasy™ EGFP plasmid. The resulting
construct was recombined with adenoviral genome using the Vogelstein
kit. Palates were transfected as above. All viruses were replication defec-
tive. (3) GFP DN Smad4 adenovirus. A recombinant adenovirus expressing
a DN mutant Smad4 (AdMSmad4, pCMV5/Smad4) (1–514), a gift of Dr.
D.M. Simeone (University of Michigan, Ann Arbor, MI), containing a
COOH-terminal truncated DN Smad4 gene, was subcloned into the ade-
novirus vector. The DN Smad4 construct was bluntly ligated into the
EcoRV site of the shuttle vector (pAdTrack) as described by He et al.
(1998). Recombination was confirmed using multiple restriction enzyme
digest analyses. The linearized recombinant plasmid was packaged into in-
fectious adenoviral particles by transfecting HEK 293 cells using Lipo-
fectAMINE™ PLUS reagent, and the recombinant adenovirus was har-
vested after 7–10 d. Recombinant adenoviruses were screened for
expression of the introduced genes by fluorescent microscopy. (4) 2 ng/ l
anti–mouse TGF 3-blocking antibody (R&D Systems). (5) 2 ng/ l recombi-
nant TGF 3 (R&D Systems). (6) AS  -catenin oligonucleotides 5 -
GGAGTTTAACCACAACAGGCAGTCC-3  and control sense 5 -CCT-
GACGGACAACACCAATTTGAGG-3 , as described by Haertel-Wiesmann
et al. (2000), used by Brunet et al. (1995), were tested in our laboratory. (7)
15  M MEK1/2 inhibitor UO126 (Cell Signaling). (8) RhoA inhibitor C3
(Calbiochem). Palates were treated with 10  g/ml LipofectAMINE™ for 2 h
before C3 treatment. The C3 exoenzyme (30  m), a toxin derived from C.
botulinum, is an ADP ribosyltransferase that catalyzes mono-ADP ribosy-
lation of the small GTP-binding proteins Rho (A, B, and C) at asparagine 41
(Wilde et al., 2002). Because ADP ribosylation occurs in the putative effec-
tor region of Rho, this modification interferes with correspondent Rho
GTPase-dependent signaling pathways (Wilde et al., 2002). C3 is widely
used in cell biology as a convenient tool to specifically inactivate Rho pro-
teins (Borbiev et al., 2000).
Palatal shelves were routinely incubated 1 h before placing them to-
gether, and the medium was then changed every 24 h. Adenovirus, AS
 -catenin, and C3 treatments (Lu et al., 2001) in single palates were con-
tinued for 48 h. Palates were fixed in Bouin’s fixative before embedding in
paraffin or cryomold tissue freezing medium, TBS (Triangle Biomedical
Sciences) for sections. We only collected prime sections from the middle
one third of the palate.
Evaluation of adenovirus
All our adenovirus experiments were based on earlier published experi-
ments (Kim and Hay, 2001) in which DLD1 cells exposed to 200  l/ml
full-length LEF1 virus were shown to undergo EMT promptly and to ex-
press LEF1 (Kim and Hay, 2001). Previously, we did tests to confirm the ti-
tration and dilution, and optimized the protocol. Adenovirus treatment
continued in single palatal shelves until GFP protein is visualized by mi-
croscopy confirming viral protein production, and then shelves were
placed together for further incubation. Most cultured palates were col-
lected at 12–60 h. We found that the virus does not hurt the cells, and
there are no morphological changes due to viral infection
The LEF1 construct used for the DN virus probe specifically lacks its B
box for nuclear export. The DN LEF1 plasmid was also administrated in
200  l/ml virus and effectively blocked LEF1 mRNA expression (Fig. 4 A,
d). The DN Smad4 virus, which lacks COOH terminus for its nuclear trans-
location, abolished both Smad4 and Smad2 from the nuclei of the palate
MEE cells. Palatal MEE cells were stained with Smad4 antibody to evaluate
effects of DN Smad4 (Zhang et al., 2001), which shows that protein ex-
pression is exclusively in the cytoplasm of the MEE cells (Fig. 6 F). Both
DN LEF1 and DN Smad4 significantly reduce LEF1 expression (Fig. 4 A, d;
Fig. 4 B, c).
Evaluation of chemical inhibitors
Two chemical inhibitors were used at concentrations recommended by the
manufacturer that had been shown to eliminate RhoA by C3 (Lu et al.,
2001) and MEK1/2 with U0126 (Chow et al., 2001). To optimize dose and
confirm the effects of TGF 3-blocking antibody, recombinant TGF 3, AS
 -catenin, and U0126 and C3, we stained the palatal sections with TGF 3
antibody (Santa Cruz Biotechnology, Inc.), anti- -catenin antibody (Sigma-
Aldrich), phospho-p44/42 MAPK (Thr202/Tyr204) E10 antibody (Cell Sig-
naling), and anti-RhoA antibody, respectively.
LCM
To study the EMT process in palatal MEE, uncontaminated by existing mes-
enchyme, analysis of pure epithelial and mesenchymal cell populations is
necessary. We isolated epithelial cells dissected from the MEE of 300 pairs
of palates by highlighting individual cells from the intact MEE and trans-
forming MEE using Leica software. (1) Cutting and staining. The block is at-
tached to the chuck in the cryostat with OCT™. 8- m sections were cut
onto special slides (Leica) coated with plastic foil. We used HistoGene™
LCM staining (Arcturus) for frozen sections. HistoGene™ stains nuclei
bright blue without degrading nucleic acids and yields high quality RNA.
Stained sections were immediately processed for LCM. (2) Dissection. Us-
ing built-in software (IM1000) of Leica LCM, we were able to highlight MEE
cells and transforming epithelial cells. Highlighted cells were cut using a la-
ser beam (7.2 mW at 30 Hz) and collected in sterile plastic tubes. After mi-
crodissection (roughly 1,000 cells from each sample), the collecting tube
containing cells in lysis buffer ( -ME and RLT; 50  l buffer with 0.04% pro-
teinase K, 10 mM Tris-HCL, pH 8.0, 1 mM EDTA, and 1% Tween 20) is
capped and homogenized. RNeasy
® mini kit (QIAGEN) was used for total
RNA extraction and purification. Extracted RNA was purified and quanti-
fied by spectrophotometry. All 260/280-nm ratios were above 1.8–2.2.
Real-time PCR
Total RNA samples of epithelial cells from different stages of palatogenesis
were prepared and reverse transcribed into cDNA, and real-time PCR was
performed as described by Scanlan et al. (2002).
If the  CT values are the same, no change in the amount of the LEF1
gene in the transforming palatal MEE cells relative to single untransformed
palatal MEE cells has occurred. If a difference between the two  CT values
is observed, the amount of the LEF1 gene molecule has increased or de-
creased, and this value is incorporated into a Microsoft
® Excel program to
generate statistics and graphs representing actual value of X, which is
equal to 2
   CT. Graph bar represents quantitative and numerical average
value of X (n   300), where X    2
ÓÓCT [ÓÓ CT   {CT LEF1 palate   CT GAPDH
palate}    {CT LEF1 single    C T GAPDH single}]. LEF1: sense, 5 -CCCACACGGA-
CAGTGACCTA-3 ; antisense, 5 –TGGGCTCCTGCTCCTTTCT-3 . Taq-
Man
® probe: 5 -FAM-TGCACGTGAAGCCTCAACACGAACA-VIC-3 ; 5 -
FAM-AGCCACATCGCTCAGACACCATGG-VIC-3 . GAPDH: sense, 5 -
CCTGTTCGACAGTCAGCCG-3 ; antisense, 5 -CGACCAAATCCGTTG-
ACTCC-3 . Immunofluorescence staining was used as follows: rabbit poly-
clonal anti- -catenin antibody (1:1,000; Sigma-Aldrich), goat polyclonal
anti-Smad2 antibody (1:100; Santa Cruz Biotechnology, Inc.), rabbit poly-
clonal anti-phospho-Smad2 antibody (1:100; Cell Signaling; recognizes
endogenous Smad2 of Ser 465 and 467 phosphorylation); and rabbit poly-
clonal anti-Smad4 antibody (1:200; Santa Cruz Biotechnology, Inc.).
Sections are blocked for 3 h at RT with 2% normal goat serum or 5%
normal rabbit serum, depending on secondary antibody in PBS, and then
incubated with primary antibody (e.g., mouse monoclonal anti- -catenin
antibody at 1:1,000) at 4 C overnight. The titers of the primary antibodies
are optimized by trial and error. Sections are washed in PBS three times
before they are incubated at RT with secondary antibody (1:200) for 2 h.
Rhodamine (Pierce Chemical Co.) was conjugated for  -catenin antibody
and phospho-Smad2 antibody or fluorescence (Pierce Chemical Co.) for
 -catenin antibody and Smad2 antibody. Sections were then washed three
times in PBS followed by three times in de-ionized water and were
mounted in Vectashield
® (Vector Laboratories). A microscope (ES1000; Ni-
kon) was used to image rhodamine- and fluorescein-conjugated antibody
by fluorescence.
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